MX2021000133A - Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. - Google Patents
Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa.Info
- Publication number
- MX2021000133A MX2021000133A MX2021000133A MX2021000133A MX2021000133A MX 2021000133 A MX2021000133 A MX 2021000133A MX 2021000133 A MX2021000133 A MX 2021000133A MX 2021000133 A MX2021000133 A MX 2021000133A MX 2021000133 A MX2021000133 A MX 2021000133A
- Authority
- MX
- Mexico
- Prior art keywords
- drugs
- new
- repurposing
- schizophrenia
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03003—D-Amino-acid oxidase (1.4.3.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
- G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
- G01N2333/90644—D-Amino acid oxidase (1.4.3.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Abstract
La invención utiliza la estrategia de detección selectiva virtual para buscar fármacos que se encuentren actualmente en el mercado como un reposicionamiento de los fármacos para la terapia de esquizofrenia. La estrategia de reposicionamiento de fármacos encuentra nuevos usos distintos de las indicaciones médicas originales de los fármacos existentes. Encontrar nuevas indicaciones para tales fármacos beneficiará a los pacientes que necesitan una nueva terapia potencial con mayor prontitud, ya que los fármacos conocidos usualmente tienen perfiles farmacocinéticos y de seguridad aceptables. En este estudio, el reposicionamiento de fármacos comercializados para el inhibidor de la DAAO como una nueva terapia de esquizofrenia se realizó con la detección selectiva virtual de fármacos comercializados y de sus metabolitos. Los fármacos y compuestos identificados y disponibles también se confirmaron con un ensayo in vitro enzimático de inhibición de la DAAO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461986480P | 2014-04-30 | 2014-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000133A true MX2021000133A (es) | 2021-03-25 |
Family
ID=54359315
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011551A MX2016011551A (es) | 2014-04-30 | 2015-04-30 | Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. |
MX2021000133A MX2021000133A (es) | 2014-04-30 | 2016-09-06 | Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011551A MX2016011551A (es) | 2014-04-30 | 2015-04-30 | Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9868975B2 (es) |
EP (2) | EP3498275B1 (es) |
JP (2) | JP2017524143A (es) |
KR (2) | KR20160147868A (es) |
CN (2) | CN112773798B (es) |
AU (1) | AU2015253099B2 (es) |
CA (1) | CA2946153C (es) |
DK (1) | DK3137658T3 (es) |
ES (2) | ES2911879T3 (es) |
IL (1) | IL248567B (es) |
MX (2) | MX2016011551A (es) |
PT (1) | PT3137658T (es) |
SG (2) | SG10202102125SA (es) |
TW (1) | TWI675660B (es) |
WO (1) | WO2015168346A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL248567B (en) * | 2014-04-30 | 2022-08-01 | Univ Nat Taiwan | Use of compounds known as d-amino acid oxidase inhibitors |
WO2018053161A1 (en) | 2016-09-14 | 2018-03-22 | National Taiwan University | Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors |
CN108143734A (zh) * | 2018-02-09 | 2018-06-12 | 南京中医药大学 | 阿莫地喹及其药学上可接受的盐在制备用于治疗阿尔茨海默病的药物中的应用 |
CN110297839B (zh) * | 2019-06-25 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | 药物适应症的查询方法、装置、计算机设备和存储介质 |
CA3166147A1 (en) * | 2021-06-23 | 2022-12-23 | Yoda Pharmaceuticals Inc. | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619652A (en) | 1982-12-23 | 1986-10-28 | Alza Corporation | Dosage form for use in a body mounted pump |
JPH0347123A (ja) | 1989-05-05 | 1991-02-28 | G D Searle & Co | インドール―2―カルボキシレート化合物類を含有するcns疾患治療用組成物 |
GB9208492D0 (en) | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
GB9321221D0 (en) | 1993-10-14 | 1993-12-01 | Glaxo Spa | Heterocyclic compounds |
CN1207721A (zh) * | 1995-11-13 | 1999-02-10 | 板井昭子 | 生理活性化合物的设计方法 |
MXPA03005130A (es) * | 2000-12-07 | 2004-12-06 | Neuromolecular Inc | Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda. |
US20030162825A1 (en) | 2001-11-09 | 2003-08-28 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
WO2003097011A1 (en) * | 2002-05-17 | 2003-11-27 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
JP2007529468A (ja) | 2004-03-16 | 2007-10-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンズイソオキサゾール |
ATE425791T1 (de) * | 2005-07-29 | 2009-04-15 | Rottapharm Spa | Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten |
JP2009511462A (ja) * | 2005-10-06 | 2009-03-19 | メルク シャープ エンド ドーム リミテッド | D−アミノ酸酸化酵素阻害剤として神経変性および精神疾患を治療するための縮合ピロールカルボン酸の使用 |
WO2007070892A2 (en) | 2005-12-16 | 2007-06-21 | Ironwood Pharmaceuticals, Inc. | Useful indole compounds |
AU2007249348C1 (en) * | 2006-05-10 | 2013-01-17 | Laclede, Inc. | Compositions and methods for enzymatic treatment of lung disorders |
AU2007269646A1 (en) | 2006-06-30 | 2008-01-10 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
JP2010516697A (ja) * | 2007-01-18 | 2010-05-20 | セプラコール インク. | D−アミノ酸オキシダーゼ阻害剤 |
WO2009148564A1 (en) | 2008-06-02 | 2009-12-10 | Ironwood Pharmaceuticals Incorporated | Selenophene and selenazole carboxylic acid derivatives |
JP4462382B1 (ja) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | D−アスパラギン酸オキシダーゼおよびd−アミノ酸オキシダーゼに対する新規阻害剤 |
US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
WO2013061161A2 (en) * | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
KR101348984B1 (ko) * | 2012-01-31 | 2014-01-10 | 전남대학교산학협력단 | 박테리아 시토크롬 p450을 이용한 오메프라졸로부터 대사산물의 신규한 생산방법 및 이를 위한 조성물 |
IL248567B (en) * | 2014-04-30 | 2022-08-01 | Univ Nat Taiwan | Use of compounds known as d-amino acid oxidase inhibitors |
-
2015
- 2015-04-30 IL IL248567A patent/IL248567B/en unknown
- 2015-04-30 CN CN202011486413.7A patent/CN112773798B/zh active Active
- 2015-04-30 KR KR1020167032409A patent/KR20160147868A/ko not_active Application Discontinuation
- 2015-04-30 SG SG10202102125SA patent/SG10202102125SA/en unknown
- 2015-04-30 AU AU2015253099A patent/AU2015253099B2/en active Active
- 2015-04-30 WO PCT/US2015/028385 patent/WO2015168346A1/en active Application Filing
- 2015-04-30 TW TW104114104A patent/TWI675660B/zh active
- 2015-04-30 SG SG11201607166XA patent/SG11201607166XA/en unknown
- 2015-04-30 CA CA2946153A patent/CA2946153C/en active Active
- 2015-04-30 US US15/125,716 patent/US9868975B2/en not_active Ceased
- 2015-04-30 ES ES15786611T patent/ES2911879T3/es active Active
- 2015-04-30 US US16/401,892 patent/USRE49340E1/en active Active
- 2015-04-30 EP EP19150604.7A patent/EP3498275B1/en active Active
- 2015-04-30 ES ES19150604T patent/ES2951736T3/es active Active
- 2015-04-30 PT PT157866112T patent/PT3137658T/pt unknown
- 2015-04-30 KR KR1020227029414A patent/KR102537686B1/ko active IP Right Grant
- 2015-04-30 JP JP2017510438A patent/JP2017524143A/ja active Pending
- 2015-04-30 EP EP15786611.2A patent/EP3137658B1/en active Active
- 2015-04-30 MX MX2016011551A patent/MX2016011551A/es unknown
- 2015-04-30 CN CN201580021632.9A patent/CN106687626B/zh active Active
- 2015-04-30 DK DK15786611.2T patent/DK3137658T3/da active
-
2016
- 2016-09-06 MX MX2021000133A patent/MX2021000133A/es unknown
-
2020
- 2020-03-03 JP JP2020035496A patent/JP6941326B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018236800B2 (en) | DNA-PK inhibitors | |
PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
MX2021000133A (es) | Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
EA201692436A1 (ru) | Медицинское применение | |
CR20160035A (es) | Inhibidores de bromodominios | |
CA2983481A1 (en) | Janus kinase inhibitor | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
EA201590941A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
MX2017005861A (es) | Metodos para el control transcripcional objetivo en regiones del super mejorador. | |
PH12016502353A1 (en) | Pharmaceutical composition | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
MX2016014911A (es) | Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos. | |
TW201613577A (en) | Pharmaceutical combinations | |
PE20151329A1 (es) | Derivado de azol benceno | |
MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина |